Direct detection of activated platelets and platelet-derived microparticles in humans.
暂无分享,去创建一个
C. Abrams | S. Shattil | S J Shattil | N. Ellison | A Z Budzynski | C S Abrams | N Ellison | A. Budzynski
[1] J. Hoxie,et al. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. , 1985, The Journal of biological chemistry.
[2] A. Schmaier,et al. Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. , 1987, The American journal of physiology.
[3] G. FitzGerald,et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Shattil. Expression, regulation and detection of fibrinogen receptors on activated human platelets. , 1988, Progress in clinical and biological research.
[5] H. Gralnick,et al. Identification of platelet glycoprotein IIb/IIIa as the major binding site for released platelet-von Willebrand factor. , 1986, Blood.
[6] H. T. ten Duis,et al. Hematologic aspects of cardiotomy suction in cardiac operations. , 1980, The Journal of thoracic and cardiovascular surgery.
[7] J. Hoxie,et al. Detection of activated platelets in whole blood using activation- dependent monoclonal antibodies and flow cytometry , 1987 .
[8] C. Milstein,et al. [1] Preparation of monoclonal antibodies: Strategies and procedures , 1981 .
[9] J. George,et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. , 1986, The Journal of clinical investigation.
[10] G. FitzGerald,et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.
[11] E. Salzman,et al. Elevated Plasma Fibrinopeptide A ana Thromboxane B2 Levels During Cardiopulmonary Bypass , 1980, Circulation.
[12] V. Fuster,et al. Antithrombotic therapy: role of platelet-inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets. (first of three parts). , 1981, Mayo Clinic proceedings.
[13] G. Vilaire,et al. The in vitro synthesis of polypeptides for the platelet membrane glycoproteins IIb and IIIa. , 1987, Blood.
[14] B. Furie,et al. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. , 1984, The Journal of biological chemistry.
[15] R. McEver,et al. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. , 1984, The Journal of biological chemistry.
[16] C. Beurling-Harbury,et al. Acquired decrease in platelet secretory ADP associated with increased postoperative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. , 1978, Blood.
[17] E. Hessel,et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. , 1980, Blood.
[18] P. Wolf. The Nature and Significance of Platelet Products in Human Plasma , 1967, British journal of haematology.
[19] P. Weber,et al. Biochemical evidence of platelet activation in patients with persistent unstable angina. , 1987, Journal of the American College of Cardiology.
[20] L Roy,et al. Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.
[21] B. Lentz,et al. Expression of coagulant activity in human platelets: release of membranous vesicles providing platelet factor 1 and platelet factor 3. , 1985, Thrombosis research.
[22] A. Gotlieb,et al. Review of antiplatelet drug use in preventing restenosis following percutaneous transluminal coronary angioplasty. , 1988, The Canadian journal of cardiology.
[23] J. Malone. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon: Reilly IAG, Roy L, Fitzgerald GA. Br Med J 1986; 292:1037–1039 , 1987 .
[24] S. Khuri,et al. Hypothermia-induced reversible platelet dysfunction. , 1987, Annals of surgery.
[25] A. Girolami,et al. The release of β‐ thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery , 1981 .
[26] B. V. van Oost,et al. The effect of thrombin on the density distribution of blood platelets: detection of activated platelets in the circulation. , 1983, Blood.
[27] V. Fuster,et al. Coronary artery thrombosis in patients with unstable angina. , 1981, British heart journal.
[28] J. Dawes,et al. Platelet alpha granule depletion: findings in patients with prosthetic heart valves and following cardiopulmonary bypass surgery. , 1983, Thrombosis research.
[29] E. Blackstone,et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. , 1981, The New England journal of medicine.
[30] E. Engvall,et al. Enzyme immunoassay ELISA and EMIT. , 1980, Methods in enzymology.
[31] B. Osterud,et al. Platelet storage lesion: formation of platelet fragments with platelet factor 3 activity. , 1987, Thrombosis research.
[32] P. Newman,et al. Human platelet fibrinogen: purification and hemostatic properties. , 1985, Blood.
[33] Edward W. Merrill,et al. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces , 1986 .
[34] J. V. van Oosterhout,et al. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. , 1987, Blood.
[35] V. Fuster,et al. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts). , 1981, Mayo Clinic proceedings.
[36] L. Brass,et al. Induction of the fibrinogen receptor on human platelets by intracellular mediators. , 1987, The Journal of biological chemistry.
[37] C. Milstein,et al. Preparation of monoclonal antibodies: strategies and procedures. , 1981, Methods in enzymology.
[38] S. Karpatkin,et al. Red-cell and platelet fragmentation in idiopathic autoimmune thrombocytopenic purpura. , 1977, The New England journal of medicine.
[39] J. Moake,et al. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. , 1987, Blood.
[40] J. Westwick,et al. Investigation of the Interaction of Blood Platelets with the Coagulation System at the Site of Plug Formation In Vivo in Man - Effect of Low-Dose Aspirin , 1987, Thrombosis and Haemostasis.
[41] G. FitzGerald,et al. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. , 1986, Circulation.
[42] J. Hoxie,et al. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[43] S. P. Levine. 10 – Secreted Platelet Proteins as Markers for Pathological Disorders* , 1986 .
[44] P. Insel,et al. Expression of fibrinogen receptors during activation and subsequent desensitization of human platelets by epinephrine. , 1986, Blood.
[45] G. Köhler,et al. A better cell line for making hybridomas secreting specific antibodies , 1978, Nature.
[46] R. Montgomery,et al. Diagnosis of Bernard-Soulier syndrome and Glanzmann's thrombasthenia with a monoclonal assay on whole blood. , 1983, The Journal of clinical investigation.
[47] G. Vilaire,et al. Exposure of platelet fibrinogen receptors by ADP and epinephrine. , 1979, The Journal of clinical investigation.
[48] H. Nieuwenhuis,et al. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation , 1987 .
[49] E. Merrill,et al. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces? , 1986, Blood.
[50] P. Sims,et al. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. , 1988, The Journal of biological chemistry.
[51] S. Karpatkin,et al. Microthrombocytosis and Platelet Fragmentation Associated with Idiopathic/Autoimmune Thrombocytopenic Purpura , 1975, British journal of haematology.
[52] L. Hillis,et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. , 1981, The New England journal of medicine.
[53] J. George,et al. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. , 1986, Blood.
[54] G. FitzGerald,et al. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. , 1986, British medical journal.